Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.

TSXV:THRM - Post by User

Therma Bright Inc > Competing Test Devices.

<< Previous

Bullboard Posts

Next >>

Comment by cote101on Feb 15, 2021 11:55am

419 Views

Post# 32568296

RE:Competing Test Devices.

Smokey1958 wrote:
Another test device was authorized by HC on Friday ...and provides another piece as to the likelihood that THRMs SCV2 will be THE game changer. Developed by Assure Technologies it had already been authorized by the FDA and CE last summer. It is a rapid test but requires a blood sample .....and has not gained traction at all in either the US or Europe.

The overall number of tests under review is dropping significantly as those looking to have a PCR test authorized clearly see that has become a testing deadend.....countries already have those in place. There are still 9 rapid point of care tests under review and as stated before NONE of these meet the expectations or demand because of both expense and sample required.

As the variant types increase while the vaccination rates decrease the world still looks for some way to get back to some sense of normalcy. SCV2 has the potential to bring that to fruition.

Enjoy the rest your holiday weekend ....and GLTA!!!

Thank's Smokey-Most valuable poster here

Do you agree with me for my interpretation of this news:---------------------------------------------Here is part of the news:"The initial prospective test will test A MINIMUM OF 100 COVISAFE PROTOTYPE DEVICES using fresh saliva from the study participants to gain feedback on how the test performs in a real-life setting. This information will be used to improve the CoviSafe™ prototype at which time the final CoviSafe™ design will be locked. The final locked CoviSafe™ design will be used for a minimum of a 300 person prospective study and the data obtained will be used for regulatory approval under the Interim Order with Health Canada and the EUA with FDA and to obtain the CE mark from Europe"---------------------- My understanding is they will fabricate 100 diffrents Prototype (Device) to find the best one of those 100 devices.(Suppose that the device number 44 have the best result) After they will fabricate 300 new devices like the No:44 and proceed with the 300 test planned. Comments ???? English is not my first language, me be i read it wrong ?????
Cote101